{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prevnar-+Pneumococcal+Conjugate+Vaccine+%28PCV%29&page=2",
    "query": {
      "intervention": "Prevnar- Pneumococcal Conjugate Vaccine (PCV)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 36,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prevnar-+Pneumococcal+Conjugate+Vaccine+%28PCV%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prevnar-+Pneumococcal+Conjugate+Vaccine+%28PCV%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T18:42:55.647Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01654263",
      "title": "A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumococcal Infection"
      ],
      "interventions": [
        {
          "name": "Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "55 Years to 74 Years"
      },
      "enrollment_count": 884,
      "start_date": "2012-10-10",
      "completion_date": "2015-08-21",
      "has_results": true,
      "last_update_posted_date": "2017-03-27",
      "last_synced_at": "2026-10-05T18:42:55.647Z",
      "location_count": 7,
      "location_summary": "Decatur, Georgia • Iowa City, Iowa • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01654263"
    },
    {
      "nct_id": "NCT03207750",
      "title": "This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rotavirus Infection",
        "Rotavirus Vaccines"
      ],
      "interventions": [
        {
          "name": "Rotarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pediarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hiberix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevenar 13",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "12 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 12 Weeks"
      },
      "enrollment_count": 1280,
      "start_date": "2017-09-14",
      "completion_date": "2019-03-01",
      "has_results": true,
      "last_update_posted_date": "2020-12-29",
      "last_synced_at": "2026-10-05T18:42:55.647Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03207750"
    },
    {
      "nct_id": "NCT05844423",
      "title": "Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumococcal Vaccines"
      ],
      "interventions": [
        {
          "name": "0.5 ml dose of 1.1 mcg VAX-24",
          "type": "BIOLOGICAL"
        },
        {
          "name": "0.5 ml dose of PCV20",
          "type": "BIOLOGICAL"
        },
        {
          "name": "0.5 ml dose of 2.2 mcg VAX-24",
          "type": "BIOLOGICAL"
        },
        {
          "name": "0.5 ml dose of 2.2/4.4 mcg VAX-24",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vaxcyte, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "89 Days",
        "sex": "ALL",
        "summary": "42 Days to 89 Days"
      },
      "enrollment_count": 802,
      "start_date": "2023-03-29",
      "completion_date": "2025-08-25",
      "has_results": false,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-10-05T18:42:55.647Z",
      "location_count": 32,
      "location_summary": "Jonesboro, Arkansas • Madera, California • Tampa, Florida + 22 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Haughton",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05844423"
    },
    {
      "nct_id": "NCT00772928",
      "title": "Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diphtheria",
        "Tetanus",
        "Haemophilus Infection",
        "Pertussis",
        "Polio"
      ],
      "interventions": [
        {
          "name": "Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "89 Days",
        "sex": "ALL",
        "summary": "42 Days to 89 Days"
      },
      "enrollment_count": 1167,
      "start_date": "2003-10",
      "completion_date": "2006-11",
      "has_results": true,
      "last_update_posted_date": "2012-02-01",
      "last_synced_at": "2026-10-05T18:42:55.647Z",
      "location_count": 23,
      "location_summary": "Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 19 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00772928"
    },
    {
      "nct_id": "NCT06693895",
      "title": "A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chickenpox"
      ],
      "interventions": [
        {
          "name": "Investigational varicella vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Marketed varicella vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Measles, mumps, and rubella vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis A vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV (pneumococcal conjugate vaccine) 13",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV 20",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vaxneuvance",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "15 Months",
        "sex": "ALL",
        "summary": "12 Months to 15 Months"
      },
      "enrollment_count": 750,
      "start_date": "2024-11-26",
      "completion_date": "2026-11-23",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-10-05T18:42:55.647Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Huntington Park, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "West Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06693895"
    },
    {
      "nct_id": "NCT03942328",
      "title": "Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage III Intrahepatic Cholangiocarcinoma AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8",
        "Unresectable Hepatocellular Carcinoma",
        "Unresectable Intrahepatic Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Pheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Pneumococcal 13-valent Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Therapeutic Autologous Dendritic Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Esophagogastroduodenoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2019-09-19",
      "completion_date": "2030-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-05T18:42:55.647Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03942328"
    },
    {
      "nct_id": "NCT00622843",
      "title": "Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections",
        "Streptococcus Pneumoniae"
      ],
      "interventions": [
        {
          "name": "pneumococcal conjugate vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pneumococcal polysaccharide vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Henry M. Jackson Foundation for the Advancement of Military Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 275,
      "start_date": "2002-12",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2025-06-08",
      "last_synced_at": "2026-10-05T18:42:55.647Z",
      "location_count": 6,
      "location_summary": "San Diego, California • Washington D.C., District of Columbia • Tripler AMC, Hawaii + 3 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tripler AMC",
          "state": "Hawaii"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Lackland Air Force Base",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00622843"
    },
    {
      "nct_id": "NCT05417165",
      "title": "Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Pneumococcal 20-valent Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal Polyvalent Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seema Bhat",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2023-09-29",
      "completion_date": "2026-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-10-05T18:42:55.647Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05417165"
    },
    {
      "nct_id": "NCT06740630",
      "title": "A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chickenpox"
      ],
      "interventions": [
        {
          "name": "Investigational varicella vaccine_Lot 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational varicella vaccine_Lot 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational varicella vaccine_Lot 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Marketed varicella vaccine_Lot 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Marketed varicella vaccine_Lot 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MMR vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis A vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV (pneumococcal conjugate vaccine) 13",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV 20",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vaxneuvance",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "15 Months",
        "sex": "ALL",
        "summary": "12 Months to 15 Months"
      },
      "enrollment_count": 1840,
      "start_date": "2025-01-10",
      "completion_date": "2027-05-17",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-10-05T18:42:55.647Z",
      "location_count": 59,
      "location_summary": "Mobile, Alabama • Hot Springs, Arkansas • Sherwood, Arkansas + 50 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Sherwood",
          "state": "Arkansas"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06740630"
    },
    {
      "nct_id": "NCT00422292",
      "title": "Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningococcal Meningitis",
        "Measles",
        "Mumps",
        "Rubella",
        "Varicella"
      ],
      "interventions": [
        {
          "name": "Meningococcal Polysaccharide Diphtheria Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Measles, Mumps, Rubella and Varicella",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Months",
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "9 Months to 12 Months"
      },
      "enrollment_count": 1664,
      "start_date": "2006-12",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2016-04-14",
      "last_synced_at": "2026-10-05T18:42:55.647Z",
      "location_count": 87,
      "location_summary": "Tuscaloosa, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Atascadero",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00422292"
    }
  ]
}